Health ❯ Healthcare ❯ Patient Care
Support Systems Quality of Life Alzheimer's Disease Treatment Diabetes Care Dementia Care Alzheimer's Disease HIV Management Heart Disease Management Alzheimer's Treatment Options Kidney Disease
The decision clears a new targeted JAK/TYK2 oral pill after a 52-week trial showed measurable clinical benefit and less steroid use for some patients.